1.1Pair with platinum chemotherapy
An infused platinum compound forms DNA crosslinks that stall replication in dividing tumor cells. A checkpoint-blocking antibody reduces inhibitory signaling in tumor-reactive T cells.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
An infused platinum compound forms DNA crosslinks that stall replication in dividing tumor cells. A checkpoint-blocking antibody reduces inhibitory signaling in tumor-reactive T cells.
An inhibitor of extracellular matrix metalloproteinases reduces matrix degradation by tumor cells. A matrix-coated porous membrane measures invasion, and parallel cell counts and viability measurements verify that the reduction occurs at exposures that preserve growth and survival.
A monoclonal antibody blocks CTLA-4 binding to CD80 and CD86 on antigen-presenting cells. This preserves access to those ligands for CD28 and supports costimulation during T-cell priming.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary oncology laboratory cultures canine melanoma organoids with lymphocytes isolated from the same tumor. Replicate wells receive vehicle, a spliceosome modulator, a species-reactive PD-1 blocking antibody, or both agents. Imaging measures viable tumor area and phosphorylated MLKL in tumor cells across the four conditions.
Expose matched tumor organoid cultures containing tumor-reactive T cells to the modulator alone, the antibody alone, both agents, or vehicle. Quantify dead tumor cells by imaging a tumor-cell marker together with a membrane-impermeant dye and compare the combination with the modulator alone.
Use a monoclonal antibody that binds the extracellular domain of PD-L1 and blocks its interaction with PD-1. This reduces inhibitory signaling when a PD-1-expressing T cell encounters a PD-L1-expressing tumor cell.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The present disclosure is based on the observation that the combination of certain spliceosome modulators (e.g., pladienolide compounds) and BCL2, BCL2/BCLxL, or BCLxL inhibitors shows improved (e.g., synergistic) anticancer effects.A · US 2020/0352937 A1 · ¶ 4
Macroscopic view showed that neither polyIC nor PD-L1 Ab inhibited HCC development in this model, while no tumor nodule was even visible in the combination group.B · US 2021/0346420 A1 · ¶ 123
Without wishing to be bound by any particular theory, as described herein, pladienolide derivatives E7107 and H3B-8800 may induce potent splicing modulation of MCL1 gene, leading to reduced expression of the functional full-length protein.A · US 2020/0352937 A1 · ¶ 45
In some embodiments, the antibody is an anti-PD-L1 antibody.B · US 2021/0346420 A1 · ¶ 23
An empty cell means only that no passage was reproduced there.
Effective therapies to overcome resistance to BCL2, BCL2/BCLxL, and BCLxL inhibitors are needed.A · US 2020/0352937 A1 · ¶ 2
The present disclosure is based on the observation that the combination of certain spliceosome modulators (e.g., pladienolide compounds) and BCL2, BCL2/BCLxL, or BCLxL inhibitors shows improved (e.g., synergistic) anticancer effects.A · US 2020/0352937 A1 · ¶ 4
HCC is a chemotherapy-resistant tumor with limited treatment options, including, surgical resection, liver transplantation, and local ablation at the early stages.B · US 2021/0346420 A1 · ¶ 3
Unexpectedly, a synthetic double stranded RNA (dsRNA), polyinosinic-polycytidylic acid (polyIC), was previously identified to have a potent liver tumor-inhibitory role.B · US 2021/0346420 A1 · ¶ 5
patent.fyi, US 2026/0355180 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355180/, SHA-256 ab6330d8e14c9656fc6c6e627d184b77194e5928686877d96295550e31086450